{
    "name": "peginterferon alfa 2a",
    "comment": "Rx",
    "other_names": [
        "Pegasys",
        "Pegasys ProClick"
    ],
    "classes": [
        "Hepatitis B/Hepatitis C Agents"
    ],
    "source": "https://reference.medscape.com/drug/pegasys-peginterferon-alfa-2a-342645",
    "pregnancy": {
        "common": [
            "There are no adequate and well-controlled studies in pregnant women to inform of drug-associated risk ",
            "Combination treatment with ribavirin is contraindicated in women who are pregnant and in the male partners of women who are pregnant; significant teratogenic and/or embryocidal effects demonstrated in all animal species exposed to ribavirin "
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Therapy can cause fetal harm and should be assumed to have abortifacient potential",
                    "Nonpegylated interferon alfa-2a treatment caused abortion when given to pregnant rhesus monkeys "
                ]
            },
            {
                "type": "Pregnancy exposure registry",
                "description": [
                    "Monitors maternal and fetal outcomes of pregnancies of female patients and female partners of male patients exposed to ribavirin during pregnancy or who become pregnant within 6 months following discontinuation of ribavirin ",
                    "Encourage healthcare providers and patients to report such cases by calling 1-800-593-2214 "
                ]
            },
            {
                "type": "Pregnancy testing ",
                "description": [
                    "  ",
                    "  ",
                    "Females of reproductive potential: Perform before initiation of treatment, monthly during treatment, and for at least 6 months following treatment",
                    "Males with female partners of reproductive potential: Perform before initiation of treatment, monthly during treatment, and for at least 6 months following treatment"
                ]
            },
            {
                "type": "Contraception ",
                "description": [
                    "Females of reproductive potential: Use effective contraception during therapy; when receiving combination therapy with ribavirin, use effective contraception during treatment and for at least 6 months after last dose "
                ]
            },
            {
                "type": "Infertility",
                "description": [
                    "Based on its mechanism of action and studies in female monkeys, disruption of the menstrual cycle may occur ",
                    "No female fertility study has been performed "
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There is no information regarding drug presence in human milk, effects on breastfed infants, or on milk production",
            "The Centers for Disease Control and Prevention recommends that HIV-infected mothers not breastfeed their infants to avoid potential transmission of HIV; therefore, CHC- and CHB-infected mothers coinfected with HIV should not breastfeed their infants "
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Alfa interferons cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders",
                "Monitor closely with periodic clinical and laboratory evaluations",
                "Discontinue drug if persistently severe or worsening signs or symptoms of the above conditions are present; disorders typically resolve after stopping therapy"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Known hypersensitivity reactions (eg, urticaria, angioedema, bronchoconstriction, anaphylaxis, or Stevens-Johnson syndrome)",
                "Autoimmune hepatitis",
                "Hepatic decompensation (Child-Pugh score >6 [class B and C]) in cirrhotic patients with or without HIV coinfection before treatment",
                "Use in neonates and infants",
                "Combination therapy with ribavirin is contraindicated in females who are pregnant and men whose female partners are pregnant"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Refer to prescribing information of the other HCV antiviral drugs, including ribavirin, for their warnings and precautions",
                "May cause birth defects and/or death of the exposed fetus; patients must avoid pregnancy (female patients or female partners of male patients) while taking PEG-INF-alfa-2a and ribavirin combination therapy",
                "Life-threatening or fatal neuropsychiatric reactions may manifest and include suicide, suicidal ideation, homicidal ideation, depression, relapse of drug addiction, and drug overdose; these reactions may occur with and without history of previous psychiatric illness",
                "Hypertension, supraventricular arrhythmias, chest pain, and myocardial infarction reported; caution with pre-existing cardiovascular disease",
                "Suppresses bone marrow function and may result in severe cytopenias; ribavirin may potentiate the neutropenia and lymphopenia induced by alpha interferons; rare occurrences of aplastic anemia observed",
                "Development or exacerbation of autoimmune disorders including myositis, hepatitis, thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura, psoriasis, rheumatoid arthritis, interstitial nephritis, thyroiditis, and systemic lupus erythematosus reported",
                "May cause or aggravate endocrine disorders including hypothyroidism, hyperthyroidism, hyperglycemia, hypoglycemia, and diabetes mellitus",
                "Alpha interferons may induce or exacerbate ophthalmic disorders including decrease or loss of vision, retinopathy including macular edema, retinal artery or vein thrombosis, retinal hemorrhages and cotton wool spots, optic neuritis, papilledema and serous retinal detachment",
                "Patients with CHC with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons",
                "Exacerbations of hepatitis during hepatitis B therapy are not uncommon and are characterized by transient and potentially severe increases in serum ALT",
                "Dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis obliterans, interstitial pneumonitis, pulmonary hypertension and sarcoidosis, some resulting in respiratory failure and/or patient deaths, may be induced or aggravated by alpha interferons",
                "Serious and severe infections (bacterial, viral, or fungal), some fatal, have been reported during treatment with alpha interferons",
                "Ulcerative and hemorrhagic/ischemic colitis, sometimes fatal, have been observed within 12 weeks of starting alpha interferon treatment",
                "Pancreatitis, sometimes fatal, has occurred during alpha interferon and ribavirin treatment",
                "Severe acute hypersensitivity reactions (eg, urticaria, angioedema, bronchoconstriction, and anaphylaxis) observed",
                "Growth inhibition observed in children aged 5-17 years with CHC during combination therapy for up to 48 weeks with ribavirin, and also in children aged 3-17 years with CHB for up to 48 weeks during monotherapy"
            ],
            "specific": [
                {
                    "type": "Laboratory tests",
                    "description": [
                        "Standard hematological and biochemical laboratory tests recommended for all patients",
                        "Preform pregnancy screening for females of childbearing potential",
                        "Administer electrocardiograms if pre-existing cardiac abnormalities exist before combination treatment with ribavirin",
                        "After initiation, perform hematological tests at 2 and 4 weeks and biochemical tests at 4 weeks",
                        "Perform additional testing periodically during therapy"
                    ]
                },
                {
                    "type": "Drug interaction overview H4",
                    "description": [
                        "Peginterferon alfa-2a is a weak CYP1A2 inhibitor",
                        "Theophylline",
                        "Once-weekly peginterferon alfa-2a treatment for 4 weeks in healthy subjects was associated with a 25% increase in theophylline AUC",
                        "If coadministered, monitor theophylline serum levels and consider appropriate dose adjustments ",
                        "NRTIs",
                        "Hepatic decompensation (including fatalities) observed when patients coinfected with CHC/HIV received NRTIs ",
                        "Closely monitor for treatment-associated toxicities when peginterferon alfa-2a/ribavirin combined with other HCV antiviral drugs and NRTIs",
                        "Refer to prescribing information for other HCV antiviral drugs and the respective NRTIs for guidance regarding toxicity management",
                        "Consider dose reduction or discontinuation of peginterferon alfa-2a, ribavirin, or both if worsening toxicities observed ",
                        "Zidovudine",
                        "Coadministration may increase risk for developing severe neutropenia and/or anemia",
                        "Consider discontinuing zidovudine as medically appropriate",
                        "Consider dose reduction or discontinuation of peginterferon alfa-2a, ribavirin, or both if worsening clinical toxicities observed, including hepatic decompensation (eg, Child-Pugh >6) ",
                        "Methadone",
                        "Coadministration increases methadone levels by 10-15% from baseline ",
                        "Clinical significance unknown; monitor for potential methadone toxicity"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "alosetron",
            "description": {
                "common": "peginterferon alfa 2a will increase the level or effect of alosetron by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "deferiprone",
            "description": {
                "common": "deferiprone, peginterferon alfa 2a.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis; if an alternative is not possible, monitor absolute neutrophil count more frequently."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "duloxetine",
            "description": {
                "common": "peginterferon alfa 2a will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pexidartinib",
            "description": {
                "common": "peginterferon alfa 2a and pexidartinib both increase  Other (see comment). Avoid or Use Alternate Drug. Pexidartinib can cause hepatotoxicity. Avoid coadministration of pexidartinib with other products know to cause hepatoxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pretomanid",
            "description": {
                "common": "peginterferon alfa 2a, pretomanid.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Pretomanid regimen associated with hepatotoxicity. Avoid alcohol and hepatotoxic agents, including herbal supplements and drugs other than bedaquiline and linezolid."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ropeginterferon alfa 2b",
            "description": {
                "common": "ropeginterferon alfa 2b, peginterferon alfa 2a.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tizanidine",
            "description": {
                "common": "peginterferon alfa 2a will increase the level or effect of tizanidine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acalabrutinib",
            "description": {
                "common": "acalabrutinib, peginterferon alfa 2a.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may increase risk of myelosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clomipramine",
            "description": {
                "common": "peginterferon alfa 2a will increase the level or effect of clomipramine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clozapine",
            "description": {
                "common": "peginterferon alfa 2a will increase the level or effect of clozapine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eltrombopag",
            "description": {
                "common": "peginterferon alfa 2a will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydroxyurea",
            "description": {
                "common": "peginterferon alfa 2a, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Cutaneous vasculitic toxicities (eg, vasculitic ulcerations and gangrene) were reported during therapy with hydroxyurea in patients with a history of, or currently receiving, interferon therapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "ifosfamide, peginterferon alfa 2a.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Ifosfamide may enhance the toxicities of myelosuppressive agents. Monitor for increased risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imipramine",
            "description": {
                "common": "peginterferon alfa 2a will increase the level or effect of imipramine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lamivudine",
            "description": {
                "common": "peginterferon alfa 2a, lamivudine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of liver decompensation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lidocaine",
            "description": {
                "common": "peginterferon alfa 2a will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mexiletine",
            "description": {
                "common": "peginterferon alfa 2a will increase the level or effect of mexiletine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olanzapine",
            "description": {
                "common": "peginterferon alfa 2a will increase the level or effect of olanzapine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pegloticase",
            "description": {
                "common": "pegloticase will decrease the level or effect of peginterferon alfa 2a by  Other (see comment). Use Caution/Monitor. According to the manufacturer, potential for anti-PEG antibody development that may bind to other pegylated drugs; clinical significance unknown"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pegvaliase",
            "description": {
                "common": "pegvaliase, peginterferon alfa 2a. Other (see comment). Use Caution/Monitor. \nComment: The majority of patients treated with pegvaliase develop anti-polyethylene glycol (PEG) IgM and IgG antibodies. Risk of coadministration with different PEGylated products is unknown. There is a case report of anaphylaxis following a medroxyprogesterone acetate injectable suspension that contained PEG 3350. Carefully read all drug labels, including OTC drugs to check contents for PEG. Note: Unable to include an exhaustive product list for this interaction."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rasagiline",
            "description": {
                "common": "peginterferon alfa 2a will increase the level or effect of rasagiline by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. Recommended dose of rasagiline is 0.5mg daily in combination with CYP1A2 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ropinirole",
            "description": {
                "common": "peginterferon alfa 2a will increase the level or effect of ropinirole by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "theophylline",
            "description": {
                "common": "peginterferon alfa 2a will increase the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "peginterferon alfa 2a increases effects of warfarin by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "antipyrine",
            "description": {
                "common": "peginterferon alfa 2a will increase the level or effect of antipyrine by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "asenapine",
            "description": {
                "common": "peginterferon alfa 2a will increase the level or effect of asenapine by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "caffeine",
            "description": {
                "common": "peginterferon alfa 2a will increase the level or effect of caffeine by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "frovatriptan",
            "description": {
                "common": "peginterferon alfa 2a will increase the level or effect of frovatriptan by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ondansetron",
            "description": {
                "common": "peginterferon alfa 2a will increase the level or effect of ondansetron by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "riluzole",
            "description": {
                "common": "peginterferon alfa 2a will increase the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Fatigue",
            "percent": "56"
        },
        {
            "name": "asthenia",
            "percent": "54"
        },
        {
            "name": "Headache",
            "percent": "37"
        },
        {
            "name": "Pyrexia",
            "percent": "37"
        },
        {
            "name": "Myalgia",
            "percent": "35"
        },
        {
            "name": "Rigors",
            "percent": "28"
        },
        {
            "name": "Arthralgia",
            "percent": "24"
        },
        {
            "name": "Nausea",
            "percent": "23"
        },
        {
            "name": "vomiting",
            "percent": "22"
        },
        {
            "name": "Alopecia",
            "percent": "21"
        },
        {
            "name": "Injection site reaction",
            "percent": "19"
        },
        {
            "name": "Neutropenia",
            "percent": "19"
        },
        {
            "name": "Irritability",
            "percent": "18"
        },
        {
            "name": "anxiety",
            "percent": "17"
        },
        {
            "name": "nervousness",
            "percent": "16"
        },
        {
            "name": "Insomnia",
            "percent": "16"
        },
        {
            "name": "Depression",
            "percent": "15"
        },
        {
            "name": "Anorexia",
            "percent": "12"
        },
        {
            "name": "Diarrhea",
            "percent": "11"
        },
        {
            "name": "Dizziness",
            "percent": "91"
        },
        {
            "name": "Abdominal pain",
            "percent": "51"
        },
        {
            "name": "Pruritus",
            "percent": "49"
        },
        {
            "name": "Pain",
            "percent": "44"
        },
        {
            "name": "Influenza like illness",
            "percent": "35"
        },
        {
            "name": "Headache",
            "percent": "25"
        },
        {
            "name": "Gastrointestinal disorder",
            "percent": "24"
        },
        {
            "name": "Injection site reaction",
            "percent": "15"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "11"
        },
        {
            "name": "Fatigue",
            "percent": "11"
        },
        {
            "name": "Irritability",
            "percent": "65"
        },
        {
            "name": "Rash",
            "percent": "43"
        },
        {
            "name": "Pruritus",
            "percent": "41"
        },
        {
            "name": "Decreased appetite",
            "percent": "40"
        },
        {
            "name": "Fatigue",
            "percent": "33"
        },
        {
            "name": "asthenia",
            "percent": "30"
        },
        {
            "name": "Headache",
            "percent": "28"
        },
        {
            "name": "Pyrexia",
            "percent": "27"
        },
        {
            "name": "Myalgia",
            "percent": "25"
        },
        {
            "name": "Irritability",
            "percent": "25"
        },
        {
            "name": "anxiety",
            "percent": "24"
        },
        {
            "name": "nervousness",
            "percent": "23"
        },
        {
            "name": "Insomnia",
            "percent": "22"
        },
        {
            "name": "Alopecia",
            "percent": "20"
        },
        {
            "name": "Neutropenia",
            "percent": "19"
        },
        {
            "name": "Nausea",
            "percent": "16"
        },
        {
            "name": "vomiting",
            "percent": "14"
        },
        {
            "name": "Rigors",
            "percent": "14"
        },
        {
            "name": "Anorexia",
            "percent": "13"
        },
        {
            "name": "Injection site reaction",
            "percent": "12"
        },
        {
            "name": "Arthralgia",
            "percent": "11"
        },
        {
            "name": "Depression",
            "percent": "11"
        },
        {
            "name": "Pruritus",
            "percent": "10"
        },
        {
            "name": "Dermatitis",
            "percent": "9"
        },
        {
            "name": "Lymphopenia",
            "percent": "8"
        },
        {
            "name": "Dizziness",
            "percent": "8"
        },
        {
            "name": "Dyspnea",
            "percent": "6"
        },
        {
            "name": "Overall resistance mechanism disorders",
            "percent": "6"
        },
        {
            "name": "Anemia",
            "percent": "6"
        },
        {
            "name": "Diarrhea",
            "percent": "5"
        },
        {
            "name": "Overall resistance mechanism disorder",
            "percent": "5"
        },
        {
            "name": "Back pain",
            "percent": "5"
        },
        {
            "name": "Concentration impairment",
            "percent": "4"
        },
        {
            "name": "Dermatitis",
            "percent": "4"
        },
        {
            "name": "Dry mouth",
            "percent": "4"
        },
        {
            "name": "Sweating increased",
            "percent": "4"
        },
        {
            "name": "Memory impairment",
            "percent": "4"
        },
        {
            "name": "Thrombocytopenia",
            "percent": "3"
        },
        {
            "name": "Memory impairment",
            "percent": "3"
        },
        {
            "name": "Rash",
            "percent": "3"
        },
        {
            "name": "Decreased weight",
            "percent": "2"
        },
        {
            "name": "Dyspnea",
            "percent": "1"
        },
        {
            "name": "Cough",
            "percent": "9"
        },
        {
            "name": "Dry skin",
            "percent": "10"
        },
        {
            "name": "Vision blurred",
            "percent": "10"
        },
        {
            "name": "Hypothyroidism",
            "percent": "10"
        },
        {
            "name": "Lymphopenia",
            "percent": "10"
        },
        {
            "name": "Mood alteration",
            "percent": "10"
        },
        {
            "name": "Anemia",
            "percent": "8"
        },
        {
            "name": "Eczema",
            "percent": "8"
        },
        {
            "name": "Insomnia",
            "percent": "6"
        },
        {
            "name": "Pain",
            "percent": "6"
        },
        {
            "name": "Concentration impairment",
            "percent": "5"
        },
        {
            "name": "Dry skin",
            "percent": "5"
        },
        {
            "name": "Cough",
            "percent": "5"
        },
        {
            "name": "Decreased weight",
            "percent": "5"
        },
        {
            "name": "Rash",
            "percent": "5"
        },
        {
            "name": "Abdominal pain",
            "percent": "4"
        },
        {
            "name": "Sweating increased",
            "percent": "4"
        },
        {
            "name": "Dyspepsia",
            "percent": "4"
        },
        {
            "name": "Vision blurred",
            "percent": "1"
        },
        {
            "name": "Eczema",
            "percent": "1"
        },
        {
            "name": "Mood alteration",
            "percent": null
        },
        {
            "name": "Back pain",
            "percent": null
        },
        {
            "name": "Thrombocytopenia",
            "percent": null
        },
        {
            "name": "Dyspnea exertional",
            "percent": null
        },
        {
            "name": "Dry mouth",
            "percent": null
        },
        {
            "name": "Hypothyroidism",
            "percent": null
        },
        {
            "name": "Dyspepsia",
            "percent": null
        },
        {
            "name": "Dyspnea exertional",
            "percent": null
        }
    ]
}